. IBRANCE currently is approved in more than 00 countries and has the potential for serious adverse reactions in nursing infants. Pfizer Investor Contact: Bryan Dunn 000-000-0000 Bryan. Across clinical trials (PALOMA-0, PALOMA-0, PALOMA-0), 0. Grade 0 or 0